Ascend Wellness Holdings
AAWH
$0.600 -4.76%
Exchange: OTC | Sector: Healthcare | Industry: Drug Manufacturers Specialty Generic
Q3 2025
Published: Nov 10, 2025

Earnings Highlights

  • Revenue of $124.73M down 11.9% year-over-year
  • EPS of $-0.13 increased by 0% from previous year
  • Gross margin of 35.0%
  • Net income of -25.83M
  • "3 core pillars: profitability, sustainability and densification. Our ongoing sustainability initiative has strengthened our balance sheet and delivered measurable cost savings with well over $30 million in annual expenses eliminated ahead of schedule." - Sam Brill
AAWH
Company AAWH

Executive Summary

Ascend Wellness Holdings (AAWH) delivered a sequentially modest revenue profile for Q3 2025, with revenue of $124.7 million, down 2% quarter-over-quarter, alongside a meaningful margin expansion on an adjusted basis. Management emphasized disciplined cost management, better product mix, and a strategic pivot toward higher-margin branded products as key drivers of profitability despite ongoing top-line pressures from price compression and increased competitive discounting. Adjusted EBITDA rose 8.9% QoQ to $31.1 million, with Adjusted EBITDA margin of 24.9%, reflecting a 250 basis point sequential improvement. On the balance sheet, AAWH maintained a robust cash position ($87.3 million) and secured a $9.3 million mortgage at 8.5%, with no major maturities until 2029, while continuing to leverage a buyback program to reduce share count (β‰ˆ5 million shares repurchased year-to-date). Strategic initiatives highlighted include: (1) densification through new store openings (7 added YTD; 46 locations) with a path to 60 Ascend/partner locations within 12 months, (2) a fully integrated digital ecosystem (Ascend Pay, Ascenders Club) driving higher wallet share and loyalty, and (3) a rapidly expanding branded CPG portfolio (Effin’, High Wired, Simply Herb, Ozone, and the upcoming Honor Roll). Importantly, management signaled Q4 revenue could be modestly below Q3 while guiding Adjusted EBITDA margin to exceed 23%, supported by expected ongoing operating leverage from densification and improved product mix. The call also underscored trade-offs from regulatory delays and price competition, including ongoing debates around the hemp loophole, which could materially affect the industry landscape. This synthesis presents Ascend’s evolving model: a cost-conscious, brand-powered growth engine with optionality from strategic acquisitions and new market entries, balanced by leverage and a still-challenging macro backdrop for cannabis pricing. Based on the quantitative and qualitative data, the investment thesis centers on margin expansion and scalable growth through store densification, a premium branded portfolio, and digital customer engagement, while acknowledging the risk from regulatory dynamics and persistent price competition.

Key Performance Indicators

Revenue
Decreasing
124.73M
QoQ: -2.02% | YoY: -11.94%
Gross Profit
Decreasing
43.60M
34.96% margin
QoQ: 5.34% | YoY: -0.29%
Operating Income
Increasing
-1.33M
QoQ: -32.24% | YoY: 45.18%
Net Income
Increasing
-25.83M
QoQ: -5.81% | YoY: 8.60%
EPS
Stable
-0.13
QoQ: -8.33% | YoY: 0.00%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 124.73 -0.13 -11.9% View
Q2 2025 127.30 -0.12 -10.1% View
Q1 2025 128.00 -0.09 -10.1% View
Q4 2024 136.01 -0.08 -3.0% View
Q3 2024 141.65 -0.13 +0.3% View